How does midostaurin work?
Midostaurin is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of mast and cancer cells.
What does midostaurin target?
Midostaurin belongs to a class of drugs called multi-kinase inhibitors, which can target more than one protein in cells. While in AML that target is FLT3, in aggressive SM and related conditions the target is a mutant protein called KIT D816V, which is found in about 90% of mastocytosis cases.
What is a FLT3 inhibitor?
FLT3 inhibitors are tyrosine kinase inhibitors and are classified into first- and second-generation inhibitors based on their kinase specificity and potency. First-generation inhibitors include midostaurin and sorafenib.
Is Midostaurin a chemotherapy?
Midostaurin is a type of targeted cancer drug and daunorubicin and cytarabine are chemotherapy drugs. Midostaurin is pronounced MY-doh-STAW-rin. You pronounce daunorubicin as DAW-noh-ROO-bih-sin and cytarabine as sye-TARE-a-been. This combination of cancer drugs is a treatment for acute myeloid leukaemia (AML).
Can you drink on Midostaurin?
The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of midostaurin. is best to use birth control while being treated with midostaurin and for at least four months after your last dose. Hormonal birth control may not work as well while you are taking midostaurin.
Is Midostaurin FDA approved?
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.
How do FLT3 inhibitors work in AML?
Pim kinase inhibitors and FLT3 inhibitors show synergistic cytotoxicity in AML cells with FLT3-ITD [49,50], and Pim inhibitors restore sensitivity to FLT3 inhibitors in resistant cells . The data support combining Pim kinase inhibitors, which are currently in Phase I clinical trials, with FLT3 inhibitors.
What causes FLT3 mutation?
One common mechanism of FLT3 inhibitor resistance is development of a secondary FLT3 mutation, most commonly in the KD (58). These mutations commonly occur at gatekeep F691 and activation loop (AL) D835 residues, but can involve other KD residues I836, D839, and Y842, among others (59).
What is Leukostasis?
Leukostasis is a pathologic diagnosis in which white cell plugs are seen in the microvasculature. Clinically, leukostasis is typically diagnosed empirically when a patient with leukemia and hyperleukocytosis presents with respiratory or neurological distress.
How is Midostaurin given?
Midostaurin was given orally in a dose of 50 mg twice daily for 365 days. After consolidation, therapy with HiDAC midostaurin was continued after the last applied cycle. After alloHCT, midostaurin was started at the earliest 30 days and at the latest 100 days after transplantation.